Cover Image

Breast Cancer in a Young Female with Antipsychotic-induced Hyperprolactinemia: A Case Report

Jareer Heider Abu Hmeidan, Arief Ismael Arrowaili


Introduction: The relationship between prolactin (PRL) and breast cancer in humans has been a controversial issue for a long time. Although some animal and human in vitro studies illustrated an undeniable effect of PRL in inducing and promoting mammary cancer, epidemiological studies have been lees conclusive. There have been few reported cases of breast cancer in patients with hyperprolactinemia due to prolactinoma.

Case Presentation: We present a case of bilateral, multifocal, metastatic, triple negative breast cancer in a 33-year-old female with long-standing, antipsychotic-induced hyperprolactinemia.

Conclusion: [There is a growing body of evidence on the carcinogenic effect of prolactin on mammary tissue]. Studying tumor biology in patients with long standing hyperprolactinemia might prove useful in delineating the relationship between PRL and breast cancer in humans.


breast cancer; prolactin; anti-psychotics

Full Text:



Daniels GH, Kourides IA, Maloof F. Breast cancer in the Forbes-Albright syndrome. Acta Endocrinol (Copenh). 1976, 82:746-752

Buytaert P, Viaene P. Amenorrhea, galactorrhea, hyperprolactinemia syndrome and breast carcinoma in a young woman. Eur J Obstet Gynecol Reprod Biol. 1981, 11:341-346

Olsson H, Alm P, Kristoffersson U, Landin-Olsson M. Hypophyseal tumor and gynecomastia preceding bilateral breast cancer development in a man. Cancer. 1984, 53:1974-1977

Valette H, Agnani G. Association of lobular epithelioma and hypophyseal adenoma in a young woman. A case report. Rev Fr Gynecol Obstet. 1984, 79:739-742

Theodorakis SP, Tedesco VE, Sutherland CM. Breast cancer in a patient with prolactinoma. Surgery 1985, 98(2):367-369

Haga S, Watanabe O, Shimizu T, et al. Breast cancer in a male patient with prolactinoma. Surg Today. 1993, 23:251-255

Strungs I, Gray RA, Rigby HB, Strutton G. Two case reports of breast carcinoma associated with prolactinoma. Pathology. 1997, 29:320-323

Volm MD, Talamonti MS, Thangavelu M, Gradishar WK. Pituitary adenoma and bilateral male breast cancer: an unusual association. J Surg Oncol. 1997, 64:74-78

Forloni F, Giovilli M, Pecis C, et al. Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year-old male. J Endocrinol Invest. 2001, 24:454-459

Sato T, Muto I, Hasegawa M, et al. A rare case of invasive ductal carcinoma with hyperprolactinemia. Breast Cancer. 2007, 14:302-306

Mallawaarachchi CM, Ivanova S, Shorthouse A, Shousha S, Sinnett D. A rare case of male breast ductal carcinoma in-situ associated with prolactinoma. BMJ Case Rep. 2011, 2011.

Bushe CJ, Bradley A, Pendlebury J. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem. 2010, 47(Pt 4):292-300

Turrone P, Kapur S, Seeman M V, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002, 159:133-135

Kapur S, Langlois X, Vinken P, Megens AAHP, De Coster R, Andrews JS. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther. 2002, 302:1129-1134

Clevenger C V, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev. 2003, 24:1-27

Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev. 2005, 26:400-422

Fernandez I, Touraine P, Goffin V. Prolactin and human tumourogenesis. J Neuroendocrinol. 2010, 22:771-777

Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res. 1995, 55:2591-2595

Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 2007, 25:1482-1488

Wang PS, Walker AM, Tsuang MT, et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry. 2002, 59:1147-1154

Pattison ST, McLaren BR. Triple negative breast cancer in a male-to-female transsexual. Intern Med J. 2013, 43:203-205

Bonneterre J, Mauriac L, Weber B, et al. Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: Results of a double blind multicentre clinical trial. Eur J Cancer Clin Oncol. 1988, 24:1851-1853

Anderson E, Ferguson JE, Morten H, Shalet SM, Robinson EL, Howell A. Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. Eur J Cancer. 1993, 29:209-217


  • There are currently no refbacks.

AJCC-REP (ISSN 2572-5742)Copyright © 2012-2021. All rights reserved. Published by Ivy Union Publishing, 3204 Valley Rush Dr, Apex, North Carolina 27502, United States